Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.

Bassil N; Thaipisuttikul P; Grossberg GT

首页> 外文期刊>Expert opinion on pharmacotherapy >Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.

【24h】

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.

机译：Memantine ER，曾经每日制剂治疗阿尔茨海默病。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE OF THE FIELD: Alzheimer's disease is a progressive, degenerative brain disease. As the disease progresses, patients and caregivers face increasing problems with medication adherence. Given its relentlessly progressive nature, newer and more effective therapies for Alzheimer's disease are needed. Memantine 10 mg twice daily is the FDA-approved regimen for the treatment of moderate to severe Alzheimer's disease. AREAS COVERED IN THIS REVIEW: The goal of this article is to review the once-daily memantine ER 28 mg formulation for the treatment of Alzheimer's disease, which, by simplifying the dosage regimen, decreases the problems of medication adherence. A new extended-release formulation has been developed to improve adherence and possibly efficacy without compromising an excellent tolerability and safety profile. There is also a possibility of dose-dependent improvement/superiority in cognitive, global and behavioral measures as well as in verbal fluency with higher-dose (28 mg/day) memantine. WHAT THE READER WILL GAIN: Readers will become knowledgeable about this new dose and preparation of memantine. However, these advantages remain provisional and more research is needed to evaluate patient adherence, outcomes and caregiver burden related to twice-daily versus once-daily administration in patients with moderate to severe Alzheimer's disease. TAKE HOME MESSAGE: A new, once-daily, higher-dose preparation of memantine seems to be well tolerated and may provide additional benefits for selected patients with Alzheimer's disease.

机译：None

著录项

来源
《Expert opinion on pharmacotherapy》 |2010年第10期|共7页
作者
Bassil N; Thaipisuttikul P; Grossberg GT;
展开▼
作者单位

Department of Neurology and Psychiatry St. Louis University School of Medicine 1438 South Grand;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
入库时间 2022-08-20 18:08:29

相似文献

外文文献
专利

1. Progress in mechanisms of acetylcholinesterase inhibitors and memantine for the treatment of Alzheimer's disease [J] . Shao-Min Li, Ming-Shu Mo, Ping-Yi Xu 神经免疫与神经炎症（英文版） . 2015,第004期
2. Progress in mechanisms of acetylcholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease [J] . Shao-Min Li, Ming-Shu Mo, Ping-Yi Xu 神经免疫与神经炎症(英文版) . 2015,第001期
3. Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients [J] . Yi-fan ZHANG, Xiao-yan CHEN, Xiao-jian DAI, 中国药理学报：英文版 . 2011,第011期
4. Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features [J] . Hong-fang JI, Hong-yu ZHANG 中国药理学报：英文版 . 2008,第002期
5. Multipotent natural agents to combat Alzheimer＇s disease. Functional spectrum and structural features [J] . Hong-fang JI, Hong-yu ZHANG 中国药理学报：英文版 . 2008,第002期
6. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. [J] . Bassil N, Thaipisuttikul P, Grossberg GT Expert opinion on pharmacotherapy . 2010,第10期

机译：Memantine ER，每日一次的制剂，用于治疗阿尔茨海默氏病。
7. A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer's Disease: Two Phase I Studies in Healthy Volunteers [J] . Boinpally Ramesh, Chen Laishun, Zukin Stephen R., Clinical drug investigation . 2015,第7期

机译：美金刚缓释和多奈哌齐的新型每日一次固定剂量组合治疗中度至重度阿尔茨海默氏病：健康志愿者的两项I期研究
8. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. [J] . Schulz JB, Rainer M, Klunemann HH, Journal of Alzheimer's disease: JAD . 2011,第3期

机译：每日一次美金刚治疗对中度至重度阿尔茨海默氏病患者认知和功能沟通能力的持续影响：一项为期16周的开放标签试验的结果。
9. LC/SRM Reveals Amyloid-beta Isoforms' Metabolic Differences and Diurnal Fluctuations in Alzheimer's Disease. [C] . Kwasi G. Mawuenyega, Vitaliy Ovod, Rachel Potter, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：LC / SRM揭示淀粉样蛋白β同种型在阿尔茨海默病中的代谢差异和昼夜波动。
10. Nitrate Chimeras: A New Class of Disease-Modifying Agents for the Treatment of Alzheimer's Disease. [D] . VandeVrede, Lawren. 2014

机译：硝酸盐嵌合体：治疗阿尔茨海默氏病的新型疾病改良剂。
11. A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers [O] . Ramesh Boinpally, Laishun Chen, Stephen R. Zukin, -1

机译：美金刚缓释和多奈哌齐的每日一次固定剂量组合治疗中度至重度阿尔茨海默氏病的新方法：健康志愿者的两项I期研究
12. A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers [O] . 2015

机译：美金刚缓释和多奈哌齐的每日一次固定剂量组合治疗中度至重度阿尔茨海默病的新方法：健康志愿者的两项I期研究
13. Alzheimer's Disease. Report of the Secretary's Task Force on Alzheimer's Disease [R] . Lockman, R. F., Curran, L. E. 1984

机译：阿尔茨海默氏病。局长阿尔茨海默病专责小组的报告

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.

摘要

著录项

相似文献

相关主题

期刊订阅